
Cheiron is building an AI-native operating system for drug development, and a drug program generates thousands of artifacts.
cheiron.bioCrawled Nov 12, 2026
Cheiron is a domain-tuned AI engine for biomedical and pharmaceutical professionals, delivering fast, verifiable, and context-aware insights across research, clinical, medical affairs, and regulatory workflows.
Cheiron helps biopharma teams find sourced answers, create review-ready drafts, and review documents with verifiable outputs across complex scientific and regulatory work.
Cheiron provides an AI-powered platform for drug and biotech workflows, from research to document creation and review.
Cheiron, a Palo Alto-based startup, raises $8 million in seed funding to build an AI-powered platform consolidating fragmented drug development data. The round, led by Menlo Ventures, reflects investor confidence in replacing disjointed documents and spreadsheets with a unified software solution. The company targets streamlining workflows for pharmaceutical research teams.
Menlo Ventures leads an $8 million seed round for **Cheiron**, a company developing infrastructure to integrate all stages of drug development. The platform aims to streamline processes by connecting disparate systems in pharmaceutical research and production.
Cheiron, a Los Altos-based company, secures $8 million in seed funding to develop its operating system for drug programs. The funding supports the company’s mission to streamline pharmaceutical workflows and improve drug development processes. Cheiron’s platform integrates with existing systems to enhance efficiency in clinical trials and regulatory compliance.
Cheiron secures $8 million in seed funding from Menlo Ventures to develop an operating system for drug programs. The platform aims to streamline drug development workflows and improve efficiency in clinical trials. The company targets pharmaceutical companies and biotech firms seeking to optimize their drug program operations.
Cheiron secures $8 million in seed funding from Menlo Ventures to develop a software platform for managing drug development programs. The company aims to streamline operations in pharmaceutical research and clinical trials. Menlo Ventures leads the investment round, supporting Cheiron’s vision of creating an integrated system for drug programs.